How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
26
LEXX Quote, Financials, Valuation and Earnings
Last price:
$0.73
Seasonality move
:
28.99%
Day range:
$0.71 - $0.78
52-week range:
$0.46 - $1.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
28.08x
P/B ratio:
3.87x
Volume:
108.9K
Avg. volume:
1.1M
1-year change:
-55.32%
Market cap:
$19M
Revenue:
$705.9K
EPS (TTM):
-$0.57
Analysts' Opinion
-
Consensus RatingLexaria Bioscience Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.50, Lexaria Bioscience Corp. has an estimated upside of 489.01% from its current price of $0.76.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $0.76.
Fair Value
-
According to the consensus of 1 analyst, Lexaria Bioscience Corp. has 489.01% upside to fair value with a price target of $4.50 per share.
LEXX vs. S&P 500
-
Over the past 5 trading days, Lexaria Bioscience Corp. has underperformed the S&P 500 by -5.35% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Lexaria Bioscience Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lexaria Bioscience Corp. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Lexaria Bioscience Corp. reported revenues of --.
Earnings Growth
-
Lexaria Bioscience Corp. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Lexaria Bioscience Corp. reported earnings per share of -$0.07.
Enterprise value:
14.3M
EV / Invested capital:
3.09x
Price / LTM sales:
28.08x
EV / EBIT:
--
EV / Revenue:
27.40x
PEG ratio (5yr expected):
-0.08x
EV / Free cash flow:
-1.63x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$443.2K
Return On Assets:
-152.41%
Net Income Margin (TTM):
-2069.41%
Return On Equity:
-189.86%
Return On Invested Capital:
-186.06%
Operating Margin:
-2155.4%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-11-30 | 2024-11-30 | 2025-11-30 | 2024-11-30 | 2025-11-30 | |
| Income Statement | ||||||
| Revenue | $346.7K | $496.9K | $522K | $183.9K | -- | |
| Gross Profit | $186.2K | $413.6K | $443.2K | $148K | -$24.2K | |
| Operating Income | -$6.6M | -$7.2M | -$10.5M | -$2.6M | -$1.6M | |
| EBITDA | -$6.4M | -$7.1M | -$10.5M | -$2.6M | -$1.5M | |
| Diluted EPS | -$1.01 | -$0.49 | -$0.57 | -$0.16 | -$0.07 | |
| Period Ending | 2021-11-30 | 2022-11-30 | 2023-11-30 | 2024-11-30 | 2025-11-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $10.9M | $5.4M | $2.7M | $8.8M | $5.4M | |
| Total Assets | $11.7M | $6.2M | $3.6M | $9.8M | $6.1M | |
| Current Liabilities | $237.7K | $281.5K | $124.5K | $297.8K | $1.5M | |
| Total Liabilities | $277.3K | $281.5K | $254K | $399.7K | $1.5M | |
| Total Equity | $11.5M | $5.9M | $3.4M | $9.4M | $4.5M | |
| Total Debt | $47.4K | -- | $129.5K | $101.9K | $70.8K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-11-30 | 2024-11-30 | 2025-11-30 | 2024-11-30 | 2025-11-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$6.5M | -$8.7M | -$2.7M | -$984.1K | |
| Cash From Investing | -- | -$186.4K | -$210.3K | -$37.8K | -$5.1K | |
| Cash From Financing | -- | $12.8M | $5.2M | $4.3M | $3.5M | |
| Free Cash Flow | -- | -$6.7M | -$8.8M | -$2.8M | -$989.2K | |
LEXX
Sector
Market Cap
$19M
$25.9M
Price % of 52-Week High
39.98%
51.6%
Dividend Yield
0%
0%
Shareholder Yield
-21.33%
-1.66%
1-Year Price Total Return
-55.32%
-18.99%
Beta (5-Year)
0.631
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.79
200-day SMA
Sell
Level
$0.99
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$0.73
Relative Strength Index (RSI14)
Sell
Level
48.07
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-45.3708
50-day SMA
Sell
Level
$0.89
MACD (12, 26)
Buy
Level
0.18
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-23.168)
Sell
CA Score
(Annual)
Level (-6.8793)
Buy
Beneish M-Score
(Annual)
Level (-5.034)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (19.2887)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the IP licensing segment which generates revenue from customers by licensing its proprietary DehydraTECH technology. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.
Stock Forecast FAQ
In the current month, LEXX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LEXX average analyst price target in the past 3 months is $4.50.
-
Where Will Lexaria Bioscience Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lexaria Bioscience Corp. share price will rise to $4.50 per share over the next 12 months.
-
What Do Analysts Say About Lexaria Bioscience Corp.?
Analysts are divided on their view about Lexaria Bioscience Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lexaria Bioscience Corp. is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is Lexaria Bioscience Corp.'s Price Target?
The price target for Lexaria Bioscience Corp. over the next 1-year time period is forecast to be $4.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LEXX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lexaria Bioscience Corp. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of LEXX?
You can purchase shares of Lexaria Bioscience Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lexaria Bioscience Corp. shares.
-
What Is The Lexaria Bioscience Corp. Share Price Today?
Lexaria Bioscience Corp. was last trading at $0.73 per share. This represents the most recent stock quote for Lexaria Bioscience Corp.. Yesterday, Lexaria Bioscience Corp. closed at $0.76 per share.
-
How To Buy Lexaria Bioscience Corp. Stock Online?
In order to purchase Lexaria Bioscience Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get LEXX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LEXX
Sector
P/E ratio
--
23.82x
PEG ratio
-0.08x
-0.01x
P/B ratio
3.87x
1.83x
Price / LTM sales
28.08x
1.56x
Growth Metrics
LEXX
Sector
Revenue growth
-100%
4.18%
Earnings growth
54.01%
9.66%
Revenue (5-year growth)
17.53%
6.28%
Earnings forecast
--
-$0.18
Profitability
LEXX
Sector
Profitability FY 2025
$587.4K
$3.1M
Return on invested capital
-186.06%
-32.89%
Return on assets
-152.41%
-29.56%
Return on equity
-189.86%
-38.66%
Earnings Date
Last Earnings Date
Jan
30
Next Earnings Date
Jan
30
Estimated Next Earnings Date
May
1
Balance Sheet
LEXX
Sector
Total cash
$4.4M
$25.2M
Short term investments
$55.8K
$25.1M
Total assets
$4.2M
$73M
Long term debt
$70.8K
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
